Mobile

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease

Update Il y a 4 ans
Reference: EUCTR2008-003460-19

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To investigate the overall response rate and safety data of RO5072759 (1000mg flat dose) given as monotherapy in patients with relapsed CD20+ indolent NHL compared with rituximab(375mg/m2) monotherapy.

Inclusion criteria

  • Patients with CD20+ Non-Hodgkin’s Lymphoma and Leukemia

Links